Chimeric IL‐6/4R‐LL37 Engineered Macrophages Achieve Synchronized Inflammation Control and Antimicrobial Defence in Sepsis
- 1Department of Bone and Joint Surgery Department of Orthopedics Renji Hospital Shanghai Jiaotong University School of Medicine Shanghai China
- 2Department of Interventional Oncology Renji Hospital Shanghai Jiao Tong University School of Medicine Shanghai China
Abstract
Treatment of septic patients is confronted with complex immune dysregulation: excessive pro‐inflammatory responses trigger cytokine storm leading to organ damage and high mortality, while concurrent and persistent immune dysfunction manifesting as T cell exhaustion, monocyte and macrophage functional suppression, and impaired antigen presentation significantly increases the risk of secondary infections. Current clinical therapeutic strategies can effectively control infection and cytokine storm, but fail to resolve persistent T cell exhaustion, which is a critical determinant of poor long‐term survival in sepsis patients. This study reported a multifunctional engineered macrophage therapeutic strategy based on in situ LNP delivery of IL‐6/4 fusion protein and LL37 antimicrobial peptide mRNA. The IL‐6/4 fusion blocks IL‐6 mediated pro‐inflammatory signaling and activates IL‐4 mediated anti‐inflammatory pathways, reducing inflammatory injury and promoting tissue repair. LL37 antimicrobial peptide disrupts bacterial membranes to reduce bacterial burden while modulating immune responses. In sepsis mouse models, engineered macrophages significantly improved survival rates, reduced histopathological damage and organ bacterial burden, and effectively restored T cell and macrophage functions, achieving infection control, inflammation modulation, and immune reconstitution. These findings demonstrate the substantial clinical translational potential of this engineered macrophage approach for precision sepsis treatment.
Related
- Chimeric antigen receptor-engineered cell therapy for asthma: advances in targeting type 2 inflammation and translational challenges
- Exercise training inhibits inflammation in adipose tissue via both suppression of macrophage infiltration and acceleration of phenotypic switching from M1 to M2 macrophages in high-fat-diet-induced obese mice
- Microglia and border-associated macrophages play opposite roles in cerebrovascular and leukocyte responses under systemic inflammation in male mice.
- A Chemically Characterized Extract of Centipeda minima Attenuates Inflammation in Macrophages and Alleviates Osteoarthritis Progression in Rats
- Biomechanics of Red Blood Cells, Neutrophils, and Macrophages Under Oxidative Stress and Inflammation: A Narrative Review.
BibTeX
@article{jie2026chimeric,
title = {{Chimeric IL‐6/4R‐LL37 Engineered Macrophages Achieve Synchronized Inflammation Control and Antimicrobial Defence in Sepsis}},
author = {Tianyang Jie and Zheyu Zhang and Hao Zhang and Linke Bian and Penglong Zheng and Sijia Zhou and Minqi Wang and Mingyu Qu and Yufei Wang and Xinhua Qu and Bing Yue},
journal = {Advanced Science},
year = {2026},
month = aug,
doi = {10.1002/advs.77016},
url = {https://doi.org/10.1002/advs.77016},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Chimeric IL‐6/4R‐LL37 Engineered Macrophages Achieve Synchronized Inflammation Control and Antimicrobial Defence in Sepsis
AU - Tianyang Jie
AU - Zheyu Zhang
AU - Hao Zhang
AU - Linke Bian
AU - Penglong Zheng
AU - Sijia Zhou
AU - Minqi Wang
AU - Mingyu Qu
AU - Yufei Wang
AU - Xinhua Qu
AU - Bing Yue
PY - 2026
DA - 2026/08/07
JO - Advanced Science
DO - 10.1002/advs.77016
UR - https://doi.org/10.1002/advs.77016
AB - Treatment of septic patients is confronted with complex immune dysregulation: excessive pro‐inflammatory responses trigger cytokine storm leading to organ damage and high mortality, while concurrent and persistent immune dysfunction manifesting as T cell exhaustion, monocyte and macrophage functional suppression, and impaired antigen presentation significantly increases the risk of secondary infections. Current clinical therapeutic strategies can effectively control infection and cytokine storm, but fail to resolve persistent T cell exhaustion, which is a critical determinant of poor long‐term survival in sepsis patients. This study reported a multifunctional engineered macrophage therapeutic strategy based on in situ LNP delivery of IL‐6/4 fusion protein and LL37 antimicrobial peptide mRNA. The IL‐6/4 fusion blocks IL‐6 mediated pro‐inflammatory signaling and activates IL‐4 mediated anti‐inflammatory pathways, reducing inflammatory injury and promoting tissue repair. LL37 antimicrobial peptide disrupts bacterial membranes to reduce bacterial burden while modulating immune responses. In sepsis mouse models, engineered macrophages significantly improved survival rates, reduced histopathological damage and organ bacterial burden, and effectively restored T cell and macrophage functions, achieving infection control, inflammation modulation, and immune reconstitution. These findings demonstrate the substantial clinical translational potential of this engineered macrophage approach for precision sepsis treatment.
SN - 2198-3844
ER -